News

CytoDyn Announces Settlement with Amarex Clinical Research LLC

Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s…

1 year ago

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical…

1 year ago

Smart for Life Announces Appointment of Jessica Walters as Chief Marketing Officer

CMO Expected to Position Smart for Life for Long Term Growth and Utilize IP from Acquisitions to Increase Sales OpportunitiesMIAMI,…

1 year ago

Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline

Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company’s continued growth.…

1 year ago

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical…

1 year ago

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

JV will Establish Company’s 4th International CenterSAN FRANCISCO, July 09, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…

1 year ago

Organic & Natural Health Association Welcomes New President and Four New Board Members

Todd Norton Named Board President of O&N Health Todd Norton, the vice president of business development at Aker BioMarine, and…

1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (Nasdaq: MEDS) (the “Company”), announced that the Company’s board…

1 year ago

Clene Announces 1-for-20 Reverse Stock Split

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

1 year ago

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease

– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – –…

1 year ago